Issue 12/2011
Special issue: L-Dopa-associated motor complications
Content (7 Articles)
Editorial
Mechanisms underlying and medical management of l-Dopa-associated motor complications
Manfred Gerlach, Peter Riederer, Dieter Scheller
Basic Neurosciences, Genetics and Immunology - Review article
Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation
Mahmoud M. Iravani, Peter Jenner
Movement Disorders - Review article
Continuous drug delivery in early- and late-stage Parkinson’s disease as a strategy for avoiding dyskinesia induction and expression
P. Jenner, A. C. McCreary, D. K. A. Scheller
Basic Neurosciences, Genetics and Immunology - Original Article
Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on l-DOPA-induced dyskinesia
Andrzej Dekundy, Andreas Gravius, Mirko Hechenberger, Małgorzata Pietraszek, Jens Nagel, Carsten Tober, Martine van der Elst, Flora Mela, Christopher G. Parsons, Wojciech Danysz
Movement Disorders - Original Article
Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats
E. Grünblatt, W. J. Schmidt, D. K. A. Scheller, P. Riederer, M. Gerlach
Flibanserin attenuates l-DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson’s disease
Manfred Gerlach, Jürgen Beck, Peter Riederer, Maarten van den Buuse
Role of dopamine D3 and serotonin 5-HT1A receptors in l-DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease
Manfred Gerlach, Gerd D. Bartoszyk, Peter Riederer, Olivia Dean, Maarten van den Buuse